Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06557850
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-14
Brief Title:
A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Interventional Open-label Single-group Long-term Follow-up Trial of Lu AG22515 in Patients With Moderate-to-severe Thyroid Eye Disease
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will evaluate the effects of Lu AG22515 in adult men and women with moderate-to-severe thyroid eye disease TED TED is an autoimmune condition closely related to Graves Disease
In people with TED the healthy tissue behind and around the eye becomes inflamed and swollen One of the key symptoms of TED is proptosis bulging eyes The main goal of this trial is to learn whether treatment with Lu AG22515 improves proptosis in participants with moderate-to-severe TED
In people with TED the healthy tissue behind and around the eye becomes inflamed and swollen One of the key symptoms of TED is proptosis bulging eyes The main goal of this trial is to learn whether treatment with Lu AG22515 improves proptosis in participants with moderate-to-severe TED
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None